Apollomics and LaunXP Team Up to Supercharge Vebreltinib in Asia’s NSCLC Fight

March 31, 2025

DENVER, Colo., Mar 31, 2025 (247marketnews.com)- Apollomics (NASDAQ:APLM) struck a power-packed deal with LaunXP International, an affiliate of LaunXP Biomedical. The pact hands LaunXP exclusive rights to develop and commercialize vebreltinib, Apollomics’ c-Met inhibitor, paired with an EGFR inhibitor (EGFRi) for non-small cell lung cancer (NSCLC) across Asia—minus mainland China, Hong Kong, and Macau. Apollomics scores $10 million upfront within 60 days, with up to $50 million in pre-commercial milestones and royalties on sales riding on the horizon.

Vebreltinib, a potent oral c-Met blocker, zaps a key cancer pathway tied to tumor growth and EGFRi resistance—like osimertinib’s Achilles’ heel.

Dr. Guo-Liang Yu, CEO of Apollomics, said, “We are delighted to partner with LaunXP, who share our vision for the commercial opportunity for vebreltinib. EGFRi is currently the frontline treatment for many patients with NSCLC, and combining it with our c-Met inhibitor vebreltinib is expected to transform the standard of care. We believe that LaunXP can advance this development program rapidly in this patient population, bringing us closer to potentially improving outcomes for many patients with NSCLC. We will continue to seek opportunities to maximize the global opportunity for vebreltinib, both as a single agent and in combination approaches for the treatment of cancers.”

Apollomics is eyeing solo and combo vebreltinib plays elsewhere.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (APLM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.